about
Guillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital di[Rhombencephalitis caused by Listeria monocytogenes].Neurofibromatosis without Neurofibromas: Confirmation of a Genotype-Phenotype Correlation and Implications for Genetic TestingCerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey.Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry.Distribution and genotype-phenotype correlation of GDAP1 mutations in Spain.Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.Levetiracetam following liver and kidney failure in late-onset anticonvulsant hypersensitivity syndrome.Can we predict the response in the treatment of epilepsy with vagus nerve stimulation?Pure motor lumbosacral radiculopathy after intrathecal chemotherapy.Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15.Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: a retrospective study.Analysis of the CHCHD10 gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain.PET and MRI detection of early and progressive neurodegeneration in spinocerebellar ataxia type 36.Phenotypical features of a new dominant GDAP1 pathogenic variant (p.R226del) in axonal Charcot-Marie-Tooth disease.Distinct phenotypic features and gender-specific disease manifestations in a Spanish family with desmin L370P mutation.The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis.Analysis of theC9orf72Gene in Patients with Amyotrophic Lateral Sclerosis in Spain and Different Populations WorldwideCharacterising the phenotype and mode of inheritance of patients with inherited peripheral neuropathies carrying mutationsInflammatory myopathy in the context of an unusual overlapping laminopathyGenetic markers: association study in migraineEfficacy of intravenous levetiracetam as an add-on treatment in status epilepticus: a multicentric observational studySuccessful outcome of episodes of status epilepticus after vagus nerve stimulation: a multicenter studyGastrointestinal symptoms in late-onset Pompe disease: Early response to enzyme replacement therapySuccessful treatment of hypokalemic periodic paralysis with topiramateMuscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy
P50
Q30388367-A4E367CE-5DF1-441C-8CD2-C5FE769C8ED5Q30877631-E44817A7-FF88-4D3A-80CF-7858006D9E30Q34879821-6F027457-F649-48F6-93C5-805FE938697CQ37885443-B49022C4-B2E0-48BA-B278-916C2586AB31Q41109601-44DE711E-459A-4EFC-BDF2-42BD9E8BDCD3Q41158739-44BE72D5-EF4B-47EF-B67A-0F14FCB08442Q43114504-F65948EF-084D-4537-8E33-DCDE3DCBC322Q44311557-B03BA676-3227-46C8-B652-6FB778053A5BQ44473976-55CBD78D-9F62-4769-BF0F-AE2DEF97CBE5Q46543883-8EAE3D28-1F14-4F9F-9D6E-8BBDF97A6BFBQ46866734-396979DB-23CB-483B-AD7D-61AB9AB04571Q46887163-9C14217F-A655-4A37-90EF-99F664925BBEQ48090963-F97A88F8-2CB5-41E9-8997-94AFC9F2CC2DQ48424721-D7ADEA17-C388-45C2-8B4C-7C22C0235692Q50215205-13F82203-0483-437C-AF79-2783FEBDBB5AQ52571784-E0BAEBAF-2719-417F-894B-2958375FDB96Q55228908-23ADF152-88A4-4F7B-AB7D-E6078E974015Q58006957-8B47DF3E-4D46-4D9F-85E0-7FBEA20D85B2Q58556969-D42091C2-7D66-48CC-8233-65962C7402AEQ64869695-01276383-1CFE-4191-8E6B-AA3C6737A434Q71729576-CCBB81D9-489C-4594-B5BB-68034AA4E20FQ82823980-77023086-A4DB-43F2-A7DF-54E7AB39C7C7Q84792613-084B33B7-1C68-416F-9D8F-F80B5545D615Q87183819-C3FF1D5A-A8ED-46A1-82A7-4B32BCDC909FQ87450440-07B3FB77-BA59-4533-80E3-42F134133E63Q90364524-9CEA6C9C-6C12-4B09-9DE8-00A46E817920
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Julio Pardo
@ast
Julio Pardo
@en
Julio Pardo
@es
Julio Pardo
@nl
type
label
Julio Pardo
@ast
Julio Pardo
@en
Julio Pardo
@es
Julio Pardo
@nl
prefLabel
Julio Pardo
@ast
Julio Pardo
@en
Julio Pardo
@es
Julio Pardo
@nl
P106
P1153
7201755130
P21
P31
P496
0000-0001-8807-1310